NTLA insider transaction filings
Intellia Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-24. Screen NTLA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 4 filings by 3 insiders — 38,104 shares, $506,570 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 19,890 shares @ $12.60 ($250,614) by LEONARD JOHN M, filed 2026-08-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| LEONARD JOHN M — President and CEO, Director | 1 | — | 2 legs · 22,675 sh · $286,819 | — |
| Dulac Edward J III — EVP, Chief Financial Officer | 2 | — | 2 legs · 12,788 sh · $175,435 | — |
| Dube Michael P — VP, Chief Accounting Officer | 1 | — | 1 leg · 2,641 sh · $44,316 | — |
Recent Form 4 filings — Intellia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-24 | 4 | LEONARD JOHN M — President and CEO, Director | Sale (S): 19,890 @ $12.60 · Sale (S): 2,785 @ $13 | EDGAR |
| 2026-07-24 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Sale (S): 8,111 @ $11.25 | EDGAR |
| 2026-07-06 | 4 | Dube Michael P — VP, Chief Accounting Officer | Sale (S): 2,641 @ $16.78 | EDGAR |
| 2026-07-06 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Sale (S): 4,677 @ $18 | EDGAR |
| 2026-06-10 | 4 | GOODMAN JESSE — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Keresty Georgia — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Bhanji Muna — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | CHASE WILLIAM J — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Goff Brian — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Verwiel Frank — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Cohen Fred E — Director | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Dube Michael P — VP, Chief Accounting Officer | Grant/award (A): 17,250 @ $0 | EDGAR |
| 2026-03-03 | 4 | BASTA JAMES — EVP, General Counsel | Grant/award (A): 46,080 @ $0 · Sale (S): 1,211 @ $13.78 · Grant/award (A): 65,829 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Lebwohl David — EVP, Chief Medical Officer | Grant/award (A): 9,943 @ $0 · Grant/award (A): 14,204 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Grant/award (A): 61,280 @ $0 · Grant/award (A): 87,543 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Schultes Birgit C — EVP, Chief Scientific Officer | Grant/award (A): 39,200 @ $0 · Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Clark Eliana — EVP, Chief Technical Officer | Grant/award (A): 7,353 @ $0 · Sale (S): 607 @ $13.78 · Grant/award (A): 10,505 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | LEONARD JOHN M — President and CEO, Director | Grant/award (A): 156,400 @ $0 · Grant/award (A): 225,400 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Schultes Birgit C — EVP, Chief Scientific Officer | Sale (S): 8,508 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | BASTA JAMES — EVP, General Counsel | Sale (S): 10,397 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | Lebwohl David — EVP, Chief Medical Officer | Sale (S): 11,903 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | Clark Eliana — EVP, Chief Technical Officer | Sale (S): 9,515 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Sale (S): 6,379 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | Dube Michael P — VP, Chief Accounting Officer | Sale (S): 2,989 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | LEONARD JOHN M — President and CEO, Director | Sale (S): 34,146 @ $9.21 | EDGAR |
| 2026-01-07 | 4 | Cohen Fred E — Director | Purchase (P): 150,000 @ $9.35 | EDGAR |
| 2025-12-12 | 4 | LEONARD JOHN M — President and CEO, Director | Option exercise (M): 49,959 @ $6.83 · Sale (S): 49,959 @ $9.49 · Sale (S): 32,832 @ $9.47 · Sale (S): 5,355 @ $9.59 · Option exercise (M): 8,557 @ $6.83 · Option exercise (M): 49,959 (derivative) @ $0 · +1 more | EDGAR |
| 2025-10-03 | 4 | Schultes Birgit C — EVP, Chief Scientific Officer | Sale (S): 31 @ $17.38 | EDGAR |
| 2025-10-03 | 4 | Dube Michael P — VP, Chief Accounting Officer | Sale (S): 1,871 @ $17.38 | EDGAR |
| 2025-08-22 | 4 | CHASE WILLIAM J — Director | Purchase (P): 100,000 @ $10.03 | EDGAR |
| 2025-07-25 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Sale (S): 7,462 @ $14.02 | EDGAR |
| 2025-07-03 | 4 | Clark Eliana — EVP, Chief Technical Officer | Sale (S): 1,022 @ $9.82 | EDGAR |
| 2025-07-03 | 4 | Dube Michael P — VP, Chief Accounting Officer | Sale (S): 2,503 @ $9.95 | EDGAR |
| 2025-07-02 | 4 | GOODMAN JESSE — Director | Sale (S): 1,547 @ $9.56 · Sale (S): 1,547 @ $9.23 | EDGAR |
| 2025-06-18 | 4 | Keresty Georgia — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | GOODMAN JESSE — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Bhanji Muna — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Verwiel Frank — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | CHASE WILLIAM J — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Goff Brian — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Cohen Fred E — Director | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Bhanji Muna — Director | Sale (S): 265 @ $8.50 | EDGAR |
| 2025-03-04 | 4 | Clark Eliana — EVP, Chief Technical Officer | Grant/award (A): 32,000 @ $0 · Sale (S): 679 @ $8.99 · Grant/award (A): 45,714 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Dulac Edward J III — EVP, Chief Financial Officer | Grant/award (A): 47,200 @ $0 · Grant/award (A): 67,429 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Dube Michael P — VP, Chief Accounting Officer | Grant/award (A): 14,000 @ $0 | EDGAR |
| 2025-03-04 | 4 | Lebwohl David — EVP, Chief Medical Officer | Grant/award (A): 43,200 @ $0 · Grant/award (A): 61,714 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Schultes Birgit C — EVP, Chief Scientific Officer | Grant/award (A): 37,600 @ $0 · Grant/award (A): 53,714 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | BASTA JAMES — EVP, General Counsel | Grant/award (A): 40,000 @ $0 · Sale (S): 2,572 @ $8.99 · Grant/award (A): 57,143 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | LEONARD JOHN M — President and CEO, Director | Grant/award (A): 136,000 @ $0 · Grant/award (A): 196,000 (derivative) @ $0 | EDGAR |
| 2025-01-31 | 4 | Bhanji Muna — Director | Sale (S): 265 @ $9.97 | EDGAR |
Recent 8-K events — Intellia Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NTLA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →